Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.40 |
| ▸ | HTR2A | P28223 | 8/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | TPO | P07202 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25377617 | 0.87 | SLC6A4 (0.34) | SLC6A4KCNH2HTR2AIDO1SLC6A2 | |
| SCHEMBL9120134 | 0.86 | IDO1 (0.53) | SLC6A4KCNH2HTR2AIDO1SLC6A2 | |
| SCHEMBL25375857 | 0.84 | SLC6A4 (0.42) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL25374083 | 0.83 | IDO1 (0.37) | SLC6A4IDO1SLC6A2SLC6A3EPHX2 | |
| SCHEMBL23775242 | 0.79 | CHRM4 (0.45) | SLC6A4KCNH2HTR2AIDO1SLC6A2 | |
| SCHEMBL4420157 | 0.77 | KIF11 (0.47) | SLC6A4KCNH2HTR2AIDO1SLC6A2 | |
| SCHEMBL24521961 | 0.77 | EPHX2 (0.42) | SLC6A4KCNH2HTR2AIDO1EPHX2 | |
| SCHEMBL25376329 | 0.77 | IDO1 (0.42) | SLC6A4IDO1SLC6A2SLC6A3EPHX2 | |
| SCHEMBL2095744 | 0.74 | SLC6A4 (0.49) | SLC6A4KCNH2HTR2AIDO1SLC6A2 | |
| Methylsulfanylmethane SCHEMBL25377006 | 0.73 | IDO1 (0.37) | SLC6A4IDO1SLC6A2SLC6A3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4469438-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | CNKSR1, UGT1A1, REV1 | SLC6A4 4401/4885KCNH2 2824/4885HTR2A 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.